Revealing the pharmacological effects of Remodelin against osteosarcoma based on network pharmacology, acRIP-seq and experimental validation

• Published in: Scientific reports Vol. 14; no. 1; p. 3577
• Main Authors: Gao, Jia, Xu, Peili, Wang, Feng, Zhang, Wenjie, Min, Meipeng, Urba, Rafi, Fan, Lei
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 13.02.2024; Nature Publishing Group; Nature Portfolio
• Subjects: 631/154/436; 631/67/1344; Acetylation; Acetyltransferase; Bone cancer; Bone Neoplasms - drug therapy; Bone Neoplasms - genetics; Cell proliferation; Cholecystokinin; Fibroblast growth factor receptor 2; Gene expression; Genes, Overlapping; Humanities and Social Sciences; Humans; Hydrazones; Insulin-like growth factor I; multidisciplinary; N-Acetyltransferase; Network Pharmacology; Osteosarcoma; Osteosarcoma - drug therapy; Osteosarcoma - genetics; Pharmacology; Sarcoma; Science; Science (multidisciplinary); Statistical analysis; Therapeutic targets; Thiazoles; Transcriptomes
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-024-54197-4

Osteosarcoma (OS) is the most common primary malignant tumor of bone. Remodelin, an inhibitor of the N (4)-Acetylcytidine (ac4C) acetylation modifying enzyme N-acetyltransferase 10 (NAT10), has been shown to have therapeutic effects on cancer in several studies, and our previous studies have confirmed the inhibitory effect of Remodelin on OS cells, however, the mechanism of action has not yet been elucidated. We used network pharmacological analysis to quantify the therapeutic targets of Remodelin against OS. acRIP-seq and RNA-seq were performed to investigate the inhibitory activity of Remodelin on acetylation and its effect on the transcriptome after intervening in OS cells U2OS with Remodelin in vitro. Key target genes were deduced based on their pharmacological properties, combined with network pharmacology results and sequencing results. Finally, the deduced target genes were validated with vitro experiments. Network pharmacological analysis showed that 2291 OS-related target genes and 369 Remodelin-related target genes were obtained, and 116 overlapping genes were identified as Remodelin targets for OS treatment. Sequencing results showed that a total of 13,736 statistically significant ac4C modification peaks were detected by acRIP-seq, including 6938 hypoacetylation modifications and 6798 hyperacetylation modifications. A total of 2350 statistically significant mRNAs were detected by RNA-seq, of which 830 were up-regulated and 1520 were down-regulated. Association analyses identified a total of 382 genes that were Hypoacetylated-down, consistent with inhibition of mRNA acetylation and expression by Remodelin. Five genes, CASP3, ESR2, FGFR2, IGF1 and MAPK1, were identified as key therapeutic targets of Remodelin against OS. Finally, in vitro experiments, CCK-8 and qRT-PCR demonstrated that Remodelin indeed inhibited the proliferation of OS cells and reduced the expression of three genes: ESR2, IGF1, and MAPK1. In conclusion, ESR2, IGF1 and MAPK1 were identified as key therapeutic targets of Remodelin against OS. This reveals the target of Remodelin's pharmacological action on OS and provides new ideas for the treatment of OS.